Literature DB >> 8134257

Ochratoxin A impairs "postproximal" nephron function in vivo and blocks plasma membrane anion conductance in Madin-Darby canine kidney cells in vitro.

M Gekle1, H Oberleithner, S Silbernagl.   

Abstract

Ochratoxin A (OTA) is a widespread nephrotoxin which causes porcine nephropathy and is supposed to have caused the human Balkan endemic nephropathy. We performed experiments in vivo and in vitro to elucidate the mechanism of OTA action in renal epithelium. Application of OTA to male Wistar rats [1.25 mumol/(kg.day)] for 6 days led to a reduction of glomerular filtration rate (to 63% of control), an increased fractional water (194% of control), Na+ (199% of control), K+ (147% of control) and Cl- (270% of control) excretion and an increased dependence of the osmole clearance on urine flow. Acute application of OTA to rats (3 mumol/kg) increased urinary pH from 6.0 +/- 0.2 to 6.6 +/- 0.1 and urinary NaCl excretion, but decreased titratable acid excretion to 47% of control. As these in vivo findings may be the result of an action of OTA beyond the proximal tubule ("postproximal") we investigated the effect of OTA on cultured Madin-Darby canine kidney (MDCK) cells, regarded as a model of collecting duct epithelium. In confluent monolayers formed by MDCK cells OTA reduced the number of domes in a dose-dependent manner and impaired the formation of a transepithelial Cl- gradient. Electrophysiological measurements in giant MDCK cells revealed that OTA blocks fractional anion conductance of the plasma membrane with an IC50 value of 30 +/- 5 nmol/l, unmasking OTA as a naturally occurring anion conductance blocker about 20-times more effective than the most potent synthetic blocker 5-nitro-2-(3-phenylpropyl-amino) benzoic acid (NPPB) (IC50 = 600 +/- 50 nmol/l).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8134257     DOI: 10.1007/bf00374865

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  25 in total

1.  Toxicokinetics of ochratoxin A in several species and its plasma-binding properties.

Authors:  S Hagelberg; K Hult; R Fuchs
Journal:  J Appl Toxicol       Date:  1989-04       Impact factor: 3.446

2.  Experimental porcine nephropathy. Changes of renal function and structure induced by ochratoxin A- contaminated feed.

Authors:  P Krogh; N H Axelsen; F Elling; N Gyrd-Hansen; B Hald; J Hyldgaard-Jensen; A E Larsen; A Madsen; H P Mortensen; T Moller; O K Petersen; U Ravnskov; M Rostgaard; O Aalund
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1974

3.  Transepithelial transport in cell culture. A theoretical and experimental analysis of the biophysical properties of domes.

Authors:  C Tanner; D A Frambach; D S Misfeldt
Journal:  Biophys J       Date:  1983-08       Impact factor: 4.033

4.  Morphological similarities between the dog kidney cell line MDCK and the mammalian cortical collecting tubule.

Authors:  J D Valentich
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

5.  Mycotoxins. II. The constitution of ochratoxins A, B, and C, metabolites of Aspergillus ochraceus Wilh.

Authors:  K J Van der Merwe; P S Steyn; L Fourie
Journal:  J Chem Soc Perkin 1       Date:  1965-12

6.  A double-membrane model for urinary bicarbonate secretion.

Authors:  D L Stetson; R Beauwens; J Palmisano; P P Mitchell; P R Steinmetz
Journal:  Am J Physiol       Date:  1985-10

7.  Mechanism of hydrogen ion transport in the diluting segment of frog kidney.

Authors:  H Oberleithner; F Lang; G Messner; W Wang
Journal:  Pflugers Arch       Date:  1984-11       Impact factor: 3.657

8.  The pharmacokinetic profile of ochratoxin A in the rat after oral and intravenous administration.

Authors:  P Galtier; J L Charpenteau; M Alvinerie; C Labouche
Journal:  Drug Metab Dispos       Date:  1979 Nov-Dec       Impact factor: 3.922

9.  Experimental ochratoxicosis A in pigs.

Authors:  M O Tapia; A A Seawright
Journal:  Aust Vet J       Date:  1984-07       Impact factor: 1.281

10.  Cl(-)-channel blockers in the thick ascending limb of the loop of Henle. Structure activity relationship.

Authors:  P Wangemann; M Wittner; A Di Stefano; H C Englert; H J Lang; E Schlatter; R Greger
Journal:  Pflugers Arch       Date:  1986       Impact factor: 3.657

View more
  7 in total

1.  Inhibition by P1075 and pinacidil of a calcium-independent chloride conductance in conditionally-immortal renal glomerular mesangial cells.

Authors:  R D Barber; R M Henderson
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  ATP-sensitive anion channel from rat brain synaptosomal membranes incorporated into planar lipid bilayers.

Authors:  J Yuto; T Ide; M Kasai
Journal:  Biophys J       Date:  1997-02       Impact factor: 4.033

Review 3.  Molecular basis of epithelial Cl channels.

Authors:  P Fong; T J Jentsch
Journal:  J Membr Biol       Date:  1995-04       Impact factor: 1.843

4.  Effect of the mycotoxin, ochratoxin A, on hormone-stimulated ion transport in a cultured cell model of the renal principal cell.

Authors:  Bonnie L Blazer-Yost; T Aaron West; Jamie Stack; Kerrie Peck; Thomas F Lahr; Michael Gekle
Journal:  Pflugers Arch       Date:  2005-01-04       Impact factor: 3.657

5.  The mycotoxin ochratoxin A deranges pH homeostasis in Madin-Darby canine kidney cells.

Authors:  M Gekle; R Vogt; H Oberleithner; S Silbernagl
Journal:  J Membr Biol       Date:  1994-05       Impact factor: 1.843

6.  Blockade of swelling-induced chloride channels by phenol derivatives.

Authors:  M Gschwentner; A Jungwirth; S Hofer; E Wöll; M Ritter; A Susanna; A Schmarda; G Reibnegger; G M Pinggera; M Leitinger; J Frick; P Deetjen; M Paulmichl
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 7.  A review of the diagnosis and treatment of Ochratoxin A inhalational exposure associated with human illness and kidney disease including focal segmental glomerulosclerosis.

Authors:  Janette H Hope; Bradley E Hope
Journal:  J Environ Public Health       Date:  2011-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.